Repairon’s strategy is to introduce a scalable approach for the tailored construction of allografts from banked induced pluripotent stem cells (iPSC). Our first tissue engineered product is a collagen-based engineered heart muscle (EHM) patch of approximately 40x40x1 mm dimensions composed of 40 million cardiomyocytes and stromal cells, generated from induced pluripotent stem cells (iPSCs) according to proprietary protocols. EHM allografts can be produced on stock and delivered as off-the-shelf products for individual assembly to meet clinical dosing and size demands. Dose adjustment according to the individual patient requirements will be achieved by combining EHM patches. We anticipate an effective dose range of 5-20 EHM patches which corresponds to approximately 200-800 million therapeutic cells. This cell dose is chosen to address the loss of cardiomyocytes in patients with advanced heart failure. EHM emulate the structure and function of native heart muscle and are designed to survive after implantation by minimal invasive surgery onto the beating heart even in the absence of immediate perfusion, whilst stimulating vascularization to enable long-term survival, integration, and maturation.